2023 World Conference on Lung Cancer (Posters)-EP11.03. Superior Effectiveness of PD-1 Inhibitor Plus Chemotherapy vs Bevacizumab Plus Chemotherapy for NSCLC with Brain Metastases

EP11.03. Superior Effectiveness of PD-1 Inhibitor Plus Chemotherapy vs Bevacizumab Plus Chemotherapy for NSCLC with Brain Metastases - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference compares the effectiveness of PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy for non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) and without driver gene alterations. The study aimed to determine the optimal first-line treatment approach for these patients. <br /><br />The retrospective study included 155 advanced NSCLC patients with BMs who received either PD-1 inhibitor plus chemotherapy (ICIChemo group) or bevacizumab plus chemotherapy (BevaChemo group). The primary endpoints were intracranial progression-free survival (iPFS) and systemic progression-free survival (sPFS), and secondary endpoints included objective response rate (ORR) and overall survival (OS).<br /><br />Results showed that the ICIChemo group had a longer median iPFS and sPFS compared to the BevaChemo group. The hazard ratio (HR) for iPFS was 0.626 and for sPFS was 0.634, indicating a significant benefit for ICIChemo. This benefit was particularly significant in patients with PD-L1-positive expression. However, median OS was similar between the two groups.<br /><br />Both treatment regimens had similar systemic and intracranial ORR, and no newly reported adverse events were observed. Additionally, patients who received immunotherapy throughout the course of treatment had significantly improved OS compared to those who were immunotherapy-naïve.<br /><br />In conclusion, the study suggests that PD-1 inhibitor plus chemotherapy is superior to bevacizumab plus chemotherapy in terms of iPFS and sPFS for NSCLC patients with BMs lacking driver gene alterations. Immunotherapy also plays a vital role in improving OS for these patients. The findings support the use of immunotherapy as a first-line treatment option for NSCLC patients with BMs.

Asset Subtitle

Li kun Chen

Meta Tag

Speaker Li kun Chen

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

WCLC 2023 conference

PD-1 inhibitor

chemotherapy

bevacizumab

non-small cell lung cancer

NSCLC

brain metastases

driver gene alterations

first-line treatment approach

retrospective study